Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Larsucosterol · DUR-928, DV928

Other · developed by Durect

Phase 3 Most advanced trial
1 Registered trials

What is Larsucosterol?

Larsucosterol is an investigational drug studied in Hepatitis.

At a glance

Also known as
DUR-928, DV928
Drug type
Other
Therapy area
Gastroenterology
Developer
Durect
In trials of
BHC
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
UGX2V7MGMZ

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07428538 Phase 3 Hepatitis Recruiting BHC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hepatitis

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.